IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

Arun has over 15 years’ experience covering the Technology sector. During this time, he has worked with technology start-ups and as an equity analyst in investment banks and independent research firms. He was formerly a Technology Analyst for Canaccord Genuity, Altium Securities, Espirito Santo Investment Bank, Noble Group and Clear Capital. He has a dual Master’s degree in Financial Engineering and Industrial and Operations Engineering from the University of Michigan. He obtained his Bachelor’s degree in Mechanical Engineering from the Indian Institute of Technology, Bombay. He is also a CFA charterholder.

IPOs and Catalysts/Events

Merger Arb Mondays (28 Aug) - Eoflow, UMW, Boustead, Costa, Estia, Pacific Current, Golden Eagle

Merger Arb Mondays (04 Sep) - Eoflow, JSR, Seiko PMC, ENM, NWS, Costa, Symbio, Origin

Merger Arb Mondays (11 Sep) - Eoflow, Mason, Liontown, Newcrest, United Malt, OreCorp, MPI

EOFLOW/Medtronic Tender: Insulet’s US Complaint Materially Increases Deal Break Risks

EOFLOW/Medtronic Tender: Assessing the Wide Spread

EOFLOW/Medtronic Tender: Risk/Reward Profile

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Event-Driven

<ul>
<li>
<a href="https://www.smartkarma.com/entities/eoflow-co-ltd" target="_blank" data-smartkarma-citation="entities:36100:1" rel="noopener">Eoflow (294090 KS)</a> shares were up 4.4% on the back of <a href="https://www.smartkarma.com/entities/medtronic-plc" target="_blank" data-smartkarma-citation="entities:14982:1" rel="noopener">Medtronic Plc (MDT US)</a>’s earnings call comment that it expects the acquisition to close at the end of 2023.</li>
<li>The bear view is that Medtronic's messaging remained unchanged as it is still assessing <a href="https://www.smartkarma.com/entities/insulet-corp" target="_blank" data-smartkarma-citation="entities:5252:1" rel="noopener">Insulet Corp (PODD US)</a> lawsuit and the potential impact on the timing and/or pricing.</li>
<li>The bull view is that Medtronic’s comment underscores its commitment to close the transaction. It's tough to take a call on risk/reward profile – at best it's a brave buy. </li>
</ul>



Eoflow (294090 KS) shares were up 4.4% on the back of Medtronic Plc (MDT US)’s earnings call comment that it expects the acquisition to close at the end of 2023.
The bear view is that Medtronic's messaging remained unchanged as it is still assessing Insulet Corp (PODD US) lawsuit and the potential impact on the timing and/or pricing.
The bull view is that Medtronic’s comment underscores its commitment to close the transaction. It's tough to take a call on risk/reward profile – at best it's a brave buy. 


EOFLOW/Medtronic Tender: Irrational Exuberance